ResMed Inc. (RMD) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $230.69. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of RMD = $344.37 (+49.3% from the current price, the stock appears undervalued). Analyst consensus target is RMD = $296 (+28.3% upside).
Valuation: RMD trades at a trailing Price-to-Earnings (P/E) of 22.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.03.
Financials: revenue is $5.1B, +12.9%/yr average growth. Net income is $1.4B, growing at +22%/yr. Net profit margin is 27.2% (strong). Gross margin is 59.4% (+2.8 pp trend).
Balance sheet: total debt is $852M against $6.0B equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 3.44 (strong liquidity). Debt-to-assets is 10.4%. Total assets: $8.2B.
Analyst outlook: 16 / 35 analysts rate RMD as buy (46%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 48/100 (Partial), Growth 90/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 80/100 (Pass), Future 46/100 (Partial), Income 85/100 (Pass).
